Cargando…
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial
BACKGROUND: Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency ablation. For patients not eligible for such options, prognosis is poor. Sora...
Autores principales: | Gandhi, Mihir, Choo, Su Pin, Thng, Choon Hua, Tan, Say Beng, Low, Albert Su Chong, Cheow, Peng Chung, Goh, Anthony Soon Whatt, Tay, Kiang Hiong, Lo, Richard Hoau Gong, Goh, Brian Kim Poh, Wong, Jen San, Ng, David Chee Eng, Soo, Khee Chee, Liew, Wei Ming, Chow, Pierce K. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100089/ https://www.ncbi.nlm.nih.gov/pubmed/27821083 http://dx.doi.org/10.1186/s12885-016-2868-y |
Ejemplares similares
-
VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials
por: Gebski, Val, et al.
Publicado: (2017) -
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
por: Lencioni, R, et al.
Publicado: (2014) -
Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
por: Lencioni, R, et al.
Publicado: (2010) -
NIBS2020 poster Q+A
por: Bito, K, et al.
Publicado: (2021) -
Prof Dr med Nib Soehendra
Publicado: (2019)